Fig. 8: The loss of PKR rescues cell viability after depletion of PACT and ADAR1.

A Representative immunofluorescence for puromycin and G3BP1 in U2OS PACT KO or PACT/PKR dKO cells knocked down with siRNA against ADAR1. B U2OS WT, PACT KO, or PACT/PKR dKO cells knocked down with siRNA control (siCTL) or against ADAR1 (siADAR1), and the levels of puromycin-negative cells (%) were quantified by immunofluorescence. Mean values ± SD (Number of biological replicates, n = 3). P-values were calculated by two-way ANOVA. C Crystal violet staining showing the viability of U2OS WT, PACT KO, or PACT/PKR dKO cells transfected with siCTL or siADAR1. Cells were stained with Crystal violet 6 days following transfection with siRNA. D Indicated U2OS cell lines were knocked down with siCTL or siADAR1. Cell survival was quantified with Alamar blue cell viability assay 6 days following siRNA transfection. Mean values ± SD (Number of biological replicates, n = 3). P-values were calculated by two-way ANOVA. E Indicated U2OS cell lines were transfected with siRNA control (siCTL) or against ADAR1 (siADAR1). Cell growth was then monitored starting at 16 h following siRNA transfection. 9 image fields were analyzed per well. Mean values ± SD (Number of biological replicates, n = 3). Source data are provided as a Source Data file.